NCCN Guidelines® Insights - Acute Myeloid Leukemia, Version 2.2021
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to signiﬁcant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Acute Myeloid Leukemia
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Acute Myeloid Leukemia
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kaneﬁeld; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Martin S. Tallman, MD, Panel Chair, has disclosed that he receives grant/research support from AbbVie, Inc., Orsenix, Biosight, Glycomimetics, Rafael Pharmaceuticals, and Amgen; is a scientiﬁc advisor for AbbVie, Inc., Orsenix, Biosight, Daiichi-Sankyo Co., KAHR, Novartis Pharmaceuticals, and Innate Pharmaceuticals; and receives royalty from UpToDate.
Daniel A. Pollyea, MD, MS, Panel Vice Chair, has disclosed that he is a scientiﬁc advisor for AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., GlycoMimetics, Inc., Karyopharm Therapeutics, Novartis Pharmaceuticals Corporation, Kiadis, Syndax, Syros Pharmaceuticals, and Takeda Pharmaceuticals North America, Inc.
Vijaya Raj Bhatt, MBBS, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc., Incyte Corporation, Jazz Pharmaceuticals Inc., Tolero, and Pﬁzer Inc.; consulting fees from AbbVie, Inc., Genentech, Inc., Incyte Corporation, Omeros, Rigel, and Takeda Pharmaceuticals North America, Inc.; and other ﬁnancial beneﬁt from Oncoceutics.
Dale Bixby, MD, PhD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
Alexander Perl, MD, Panel Member, has disclosed that he is a scientiﬁc advisor for AbbVie, Inc., Astellas Pharma US, Inc., Celgene Corporation, Daiichi-Sankyo Co., Genentech, Inc., Actinium Pharmaceuticals, Loxo, Sumitomo Dainippon, and Syndax; receives grant/research support from AbbVie, Inc., Astellas Pharma US, Inc., Daiichi-Sankyo Co., and Fujiﬁlm Corporation; receives consulting fees from AbbVie, Inc., Astellas Pharma US, Inc., Daiichi-Sankyo Co., BeatAML LLC, Forma Therapeutics, Sumitomo Dainippon, and Syndax; and receives honoraria from AbbVie, Inc., Astellas Pharma US, Inc., Celgene Corporation, Daiichi-Sankyo Co., Genentech, Inc., Actinium Pharmaceuticals, Loxo, and Syndax.
Ndiya Ogba, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant ﬁnancial relationships.
To view all of the conﬂicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-21-002-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 10, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation